|
|
|
|
ALISO VIEJO--- Valeant Pharmaceuticals Announces FDA Has Initiated Reconsideration of Generic Efudex Approval |
| 5/15/2008 @ 8:33 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Valeant Pharmaceuticals (NYSE:VRX) today announced that the Food and Drug Administration (the FDA) has entered an administrative order “in the public interest” to stay the approval of generic fluorouracil cream 5% until May 30, 2008 “because there are outstanding questions regarding this approval that the Agency must consider.” The FDA hopes to conclude its review by May 30, 2008 and Spear has agreed to an administrative stay of its ANDA approval until May 30, 2008. According to the administrative order by the FDA, signed by Associate Commissioner for Policy and Planning, Jeffrey Shuren, “marketing, sales and shipment under ANDA 77-524 are prohibited during the pendency of this administrative stay.”
On April 11, 2008, the FDA approved an Abbreviated New Drug Application (ANDA) for a fluorouracil cream 5% sponsored by Spear Pharmaceuticals. On the same day, the FDA responded to Valeant’s December 21, 2004, Citizen Petition regarding potential generic versions of Valeant’s pioneer drug product, Efudex (fluorouracil) Cream 5%. Efudex Cream 5% is approved by the FDA for the treatment of multiple actinic or solar keratoses, and for the treatment of superficial basal cell carcinomas when conventional methods of treatment are impractical. In the Citizen Petition, Valeant requested that the FDA decline to approve generic versions of Efudex Cream 5% where the generic company has failed to provide test data comparing the generic product to Efudex Cream in patients diagnosed with superficial basal cell carcinoma, a form of skin cancer.
On April 25, 2008, Valeant filed a federal lawsuit against the Secretary of Health and Human Services, Michael O. Leavitt, and the Commissioner of the FDA, Andrew C. von Eschenbach, M.D., challenging the FDA’s denial of Valeant’s Citizen Petition and the approval of a generic to Efudex Cream 5%. Valeant requested a temporary restraining order (TRO) to suspend the FDA’s approval of Spear’s ANDA. Following an initial round of briefing, the FDA requested and obtained from the court a two week stay of the proceedings. In addition, Spear Pharmaceuticals committed to the court that it would suspend all further sales and shipment of its product for the duration of the initial stay. The FDA has since filed documents in the case indicating that in reviewing its files, the FDA has identified an issue in the Spear ANDA “concerning whether FDA has required submission of all necessary and appropriate scientific information in support of approval of Spear’s ANDA.” Now the FDA has issued an “Administrative Reconsideration and Stay of Action” of the Spear ANDA and Spear has agreed to this stay of the ANDA approval by the FDA.
Important Safety Information
Efudex (fluorouracil) Topical Solutions and Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established.
Efudex is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus. Cases of miscarriage and birth defects have been reported in women who are pregnant.
The most frequent adverse events occur locally and may include itching, burning, soreness, tenderness, scaling, and swelling. Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration. For complete Prescribing Information, please visit www.efudex.com.
About Valeant
Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com. |
| Orange County |
|
|
| |
| Tuesday, July 8, 2008 |
 |
|
IRVINE--- Intellian Technologies, Inc. Announces U.S. Launch, Opens Headquarters for the Americas in Irvine, California Posted 4:38 PM PST
IRVINE--- IT Budget, Capital Spending Growth Weakening, According to Computer Economics Posted 4:25 PM PST
SANTA ANA--- Hirsch’s Verification Station Earns Top Products Award Posted 4:24 PM PST
IRVINE-- MLB All-Star Game at Yankee Stadium - Hop-on Launches Its Disposable Cell Phone Posted 8:07 AM PST
NEWPORT BEACH--- TriZetto Teams with Eliza Corporation to Enhance Payers’ Health Communications with Members Posted 7:53 AM PST
NEWPORT BEACH--- Conexant to Acquire Freescale’s ‘Sigmatel’ Multi-Function Printer Product Lines Posted 7:52 AM PST
|
| |
| Monday, July 7, 2008 |
|
|
IRVINE--- IOGEAR's Universal Memory Banks Simplify Transfers Between Portable Multimedia Devices and Computers Posted 6:41 AM PST
TUSTIN--- FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70 (FDP) Blood Test for Monitoring Colorectal Cancer Posted 6:40 AM PST
ANAHEIM--- Location Based Technologies Receives Laboratory GSM-Type Approval for PocketFinder Products Posted 6:26 AM PST
FULLERTON--- David Gadberry Joins KETIV Technologies as Director of Technical Operations Posted 6:25 AM PST
|
| |
| Wednesday, July 2, 2008 |
|
|
IRVINE--- FarStone’s VirtualDrive Network 11.6, a CD/DVD Emulation Tower, Shares CD/DVDs and Archives Data over a Network Posted 2:17 PM PST
TUSTIN--- Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer Posted 6:47 AM PST
|
| |
| Tuesday, July 1, 2008 |
|
|
SANTA ANA--- TSYS to Class A Approve ExaDigm Payment Terminals XD1000, XD2000/XD2100SP Posted 4:38 PM PST
IRVINE--- ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc. Posted 1:32 PM PST
IRVINE--- Valicore Debuts vCoreServer Security Appliance for Embedded Systems Posted 8:13 AM PST
IRVINE--- FDA Grants Conditional Approval to Interventional Spine’s PercuDyn System IDE Application Posted 8:13 AM PST
LAKE FOREST--- Wonderware Announces New Customer First Support Offerings Including New Developer Network Posted 8:08 AM PST
COSTA MESA--- Synthetic Blood International Changes Name to Oxygen Biotherapeutics, Inc. Posted 8:07 AM PST
NEWPORT BEACH--- Wi-Fi TV Adds New and Exclusive Internet TV Stations Today Posted 8:06 AM PST
|
| |
| Monday, June 30, 2008 |
|
|
ALISO VIEJO--- Crystalens HD™ Receives FDA Approval; Posted 2:54 PM PST
TUSTIN--- Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer Posted 6:47 AM PST
NEWPORT BEACH--- Acacia Subsidiary Licenses Fraud Protection Technology to SPG Posted 6:34 AM PST
ALISO VIEJO--- Quest Software’s Jprobe Now Available as Eclipse Plug-In Posted 6:33 AM PST
IRVINE--- IBM and Epicor Collaborate on Comprehensive Retail Management Offering for Specialty Retailers Posted 6:33 AM PST
|
| |
| Friday, June 27, 2008 |
|
|
IRVINE--- New CEO At Partners Consulting and a Few Other Key Staff Changes Posted 2:27 PM PST
NEWPORT BEACH--- Acacia Subsidiary Acquires Rights to Patent for Enterprise Content Management Technology Posted 6:25 AM PST
|
| |
| Thursday, June 26, 2008 |
|
|
IRVINE--- Aktino Repeater Enables Carriers to Shatter 50 Mbps Loop Distance Limitations Posted 8:10 AM PST
|
| |
| Wednesday, June 25, 2008 |
|
|
TUSTIN--- Cherokee International Announces Appointment of David H. Robbins to its Board of Directors Posted 2:51 PM PST
NEWPORT BEACH--- Acacia Subsidiary Licenses Medical Picture Archiving and Communication System (PACS) Technology to Siemens Medical Solutions Posted 8:27 AM PST
ANAHEIM--- Location Based Technologies Commences PocketFinder Pilot Production at Jabil’s Le Mans Facility Posted 8:26 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
